GlassScriptPhysician profile
Kimberly Pickens
NPI 1437478047
$3,292.21
in general payments reported to CMS, 2019-2025
29 companies · $545 in 2025
The $545 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $638 · 2020: $405 · 2021: $529 · 2022: $415 · 2023: $312 · 2024: $447 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,304.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $821.67 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $359.59 | 2019-2025 | |
| Abbvie INC. | $329.37 | 2021-2025 | |
| Lilly USA, LLC | $219.41 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $205.25 | 2022-2025 | |
| Glaxosmithkline, LLC. | $153.65 | 2019-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $138.95 | 2019-2024 | Lokelma |
| Ironwood Pharmaceuticals, INC | $126.23 | 2019-2024 | |
| Allergan, INC. | $124.24 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.95 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $93.46 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $77.18 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $62.47 | 2019-2021 | |
| Lundbeck LLC | $60.05 | 2025 | Rexulti |
| Exact Sciences Corporation | $59.63 | 2023-2025 | Cologuard Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $55.24 | 2020-2025 | Austedo Xr, Austedo Xr |
| Ardelyx, INC. | $41.44 | 2025 | Ibsrela |
| Xeris Pharmaceuticals, INC. | $41.29 | 2021 | |
| Avanir Pharmaceuticals, INC. | $30.33 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $29.02 | 2021 | |
| Merck Sharp & Dohme LLC | $27.20 | 2019-2022 | |
| Abbott Laboratories | $22.79 | 2022 | |
| Amgen INC. | $19.87 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $18.92 | 2022 | |
| Scilex Pharmaceuticals INC. | $17.55 | 2022 | |
| Amarin Pharma, INC. | $16.49 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.15 | 2024 | Xifaxan |
| Acadia Pharmaceuticals INC | $16.01 | 2021 | |
| Inogen, INC. | $8.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Pickens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.